News and Comments

GlycoMimetics: A Lot to Tell at the ASCO Meeting

  Thursday, May 25, 2017

GlycoMimetics (GLYN) is a development-stage biotechnology company focused on cancer and sickle cell disease. The firm’s most advanced drug, rivipansel, a pan-selectin antagonist, is being developed for vaso-occlusive crisis in sickle cell disease. The product is in a Phase 3 clinical trial being conducted by GlycoMimetics’ strategic collaborator, Pfizer.  More...

Why Incyte's Product Epacadostat's Positive Results Are So Important

  Monday, May 22, 2017

As a matter of fact, we consider Incyte’s (INCY) drug epacadostat's good results extremely important. The reason? Two facts are currently settled in researchers’ and oncologists’ minds. These are:   More...

Why Akebia Therapeutics' Stock is Outperforming

  Tuesday, May 16, 2017

AKEBIA THERAPEUTICS? More...

Who Is the New FDA Commissioner? What Happened to Roche's Immunotherapy Drug?

  Thursday, May 11, 2017

AT A GLANCE More...

KITE Pharma: The Risk Versus the Reward

  Tuesday, May 09, 2017

 More...

Why Epizyme's Upcoming Presentation Is More Than Exciting

  Monday, May 08, 2017

EPIZYME More...

What Makes Merck and Array Shareholders Edgy

  Wednesday, May 03, 2017

MERCK More...

ImmunoGen: What About Now?

  Friday, April 28, 2017

ImmunoGen is one of two firms Prohost selected for investment on February 2011 based on the promises of its novel antibody-drug conjugate (ADC). An ADC drug is an antibody that carries highly potent cancer-killing agent attached to the antibody by a linker. The linker is designed to release an exceptionally toxic agent only as the ADC reaches the cancer cells in order not to harm or kill healthy cells. Our enthusiasm for ADC products emanates from their potency compared to other antibodies and to their safety and potency compared to chemotherapy drugs. The dosage of the toxic agent in the monoclonal antibody conjugate is several times that of chemotherapy, hence the superior potency and tolerability expected from the ADC products.        More...

The Market Reaction Towards the FDA Complete Response Letter Offers a Unique Investment Opportunity In Incyte

  Monday, April 17, 2017

Eli Lilly (LLY) and Incyte (INCY) announced that the FDA has issued a complete response letter for the New Drug Application (NDA) of baricitinib for moderate-to-severe rheumatoid arthritis (RA). More...

Neurocrine Biosciences: The Meaning of Ingrezza's Approval for Tardive Dyskinesia (TD)

  Thursday, April 13, 2017

On March 27, we wrote about how positive results of Neurocrine Biosciences (NBIX) drug Ingrezza on Tardive Dyskinesia (TD) will highlight Neurocrine Biosciences and its Scientists. We wrote: The results published online by The American Journal of Psychiatry demonstrate that Phase 3 trial with Ingrezza conducted on patients with tardive dyskinesia showed significant and meaningful reduction in symptoms. We elaborated on the trial that provided the results on 234 subjects with tardive dyskinesia (TD) and mood disorder (including bipolar disorder or major depressive disorder) and how the patients were treated with Neurocrine drug.    More...


Recent Postings


Archive


Tags

AstraZeneca (AZN) Herceptin LEXICON (LXRX) Intercept (ICPT) Vertex (VRTX) Rapamune Jazz Pharmaceuticals (JAZZ) Ridaforolimus Multiple Myeloma SYNTA (SNTA) Alder Biopharmaceuticals (ALDR) KITE (KITE) Sanofi-Aventis (SAN) SERES THERAPEUTICS (MCRB) Seattle Genetics (SGEN) AGOS (ARGS) ADVENTRIX (ANX) IDERA (IDRA) Auspex (ASPX) Agenus (AGEN) RenenxBio (RGNX) CRISPR Therapeutics (CRSP) Inovio (INO) Roche (ROCHE) Human Genome Sciences (HGSI) Sangamo (SGMO) Genentech Aimmune Therapeutics (AIMT) Idenix (IDIX) PORTOLA (PTLA) Prosensa (RNA) Vitae Pharmaceuticals (VTAE) ISIS (ISIS) Incyte (INCY) JOUNCE THERAPEUTICS (JNCE) Benlysta (belimumab) Dynavax (DVAX) Biogen Idec (BIIB) Biocryst (BCRX) OSI (OSIP) Cytokinetics (CYTK) Velcade (bortezomib) Editas (EDIT) Valeant Pharmaceuticals International (VRX) Telaprevir Anadys (ANDS) Ionis (IONS) SUNESIS PHARMACEUTICALS (SNSS) Merck (MRK) Regeneron (REGN) AERIE PHARMACEUTICALS Gilead (GILD) ARGOS (ARGS) galapagos (GLPG) NOVOCURE (NVCR) Abbott Laboratories (ABT) Micromet (MITI) Adaptimmune (ADAP) Mirati Therapeutics (MRTX) OncoCyte (OCX) INNOVIVA (INVA) Pluristem (PSTI) Akebia Therapeutics (AKAB) NEUROCRINE (NBIX) Ziofpharm (ZIOP) TOKAI (TKAOI) Intrexon (XON) GUARDIAN HEALTH Ariad (ARIA) Amgen (AMGN) VANDA (VNDA) C4 Therapeutics Zerenex Sarepta (SRPT) HALOZYME (HALO) REGULUS (RGLS) Bristol-Myers Squibb (BMY) Exelixis (EXEL) Epizyme (EPZM) GlaxoSmithKline (GSK) Sanofi (SNY) Galena (GALE) Human Longevity (HLI) Revlimid (lenolidamide) GlycoMimetics (GLYN) Trastuzumab-DM1 Prolor Biotech (PBTH) CompuGen (CGEN) Spike Therapeutics (ONCE) Dendreon (DNDN) BIOMARIN (BMRN) KERYX (KERX) Alnylam (ALNY) Roche (RHHBY) Endometrial Cancer Sequenom (SQNM) Agenus (AGEN Array Pharmaceuticals (ARRY) ACADIA (ACAD) Onyx (ONXX) Anacor (ANAC) Advaxis (ADXS) Ocular Therapeutix (OCUL) JUNO (JUNO) Sanofi (SNA) ZALTRAP™ MODERNA Theravance (THRX) ARCA (ABIO) Bellicum (BLCM) Theravance Bio Pharma (TBPH) ABBVIE (ABBV) Intermune (ITMN) NANTKWEST (NK) Illumina (ILMN) Elan (ELN) NEKTAR (NKTR)) CEMPRA (CEMP) PTC Therapeutics (PTCT) Tysabri ImmunoGen (IMGN) Xoma (XOMA) Global Cell Therapeutics (GBT)